Epilepsy in Medical Technology

Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)

... were presented at the International Congress for epilepsy in Budapest, Hungary. Patients not controlled ... in vital need of better seizure control." epilepsy is one of the most common neurological diseases, ... partial-onset seizures and their treatment epilepsy is one of the most common neurological diseases, ...

Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults

... need for many people living with uncontrolled epilepsy - Vimpat(R) offers hope to people with epilepsy who still have uncontrolled partial onset ... of partial-onset seizures in people with epilepsy who are 17 years and older. Vimpat(R) will be ...

VIDEO from Medialink and the Epilepsy Foundation: New Study Suggests Different Versions of the Same Epilepsy Medication Can Be Harmful

... WASHINGTON, May 12 /PRNewswire/ -- The epilepsy Foundation recently announced findings that show ... or generic-to-generic. See video from the epilepsy Foundation at: ... said Eric R. Hargis, president and CEO of the epilepsy Foundation. The study, which surveyed more ...

New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures

... Studies Presented at American epilepsy Society Annual Meeting ATLANTA, Dec. 9 ... at the 62nd annual meeting of the American epilepsy Society (AES) in Seattle. Keppra XR was ... at 1-866-822-0068 (press 9). About epilepsy ...

Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures

... of the 32nd Annual Meeting of the American epilepsy Society. Results from two identical ... About Partial Onset Seizures and epilepsy epilepsy is one of the most common disorders of the ...

Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy

... in adult patients with refractory partial-onset epilepsy when a 600 mg or 900 mg dose was added to a ... which helps control neuronal excitability. In epilepsy patients, brain cells can become overly excited, ... seizures. "Approximately 30 percent of epilepsy patients are not well-controlled despite ...

New Data Show Efficacy of Zebinix(TM) in the Treatment of Epilepsy

... with existing anti-epileptic agents." epilepsy is one of the most common neurological diseases ... of life was analysed using the Quality of Life epilepsy Inventory-31 (QOLIE-31) scale. There was ... About partial seizures and their treatment epilepsy is one of the most common neurological diseases, ...

Data Presented at AAN Support Potential for Adjunctive use of Intravenous Lacosamide as Short-Term Replacement for Oral Treatment in Partial Epilepsy

... MD, Department of Neurology, Johns Hopkins epilepsy Center, Baltimore. "In this study, short-term ... of partial onset seizures in adults with epilepsy and is currently under review. Applications for marketing authorization for lacosamide in epilepsy are supported by data from three clinical trials ...

Status of the E2007 (perampanel) Development Program

... and Focus on Neuropathic Pain and epilepsy Indications - TOKYO, April 11 /PRNewswire/ -- ... is preparing for global Phase III studies for epilepsy and conducting two Phase II studies for ... focus resources on two other ongoing indications, epilepsy and neuropathic pain, both of which have ...

Keppra XR(TM) Extended-Release Tablets Filed with the FDA

... of partial onset seizures in adults with epilepsy has been accepted for filing by the U.S. Food and ... to bringing new and innovative therapies to the epilepsy community," said Iris Loew-Friedrich, MD, PhD, ... without the limitations of twice daily dosing. epilepsy therapies with more convenient dosing schedules ...

UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets

... onset seizures in patients with uncontrolled epilepsy and was generally well tolerated," said ... as adjunctive therapy in 158 refractory epilepsy patients, 12 to 70 years of age, with partial ... one in ten patients with refractory partial onset epilepsy achieved seizure freedom," said Dr. Jukka ...

New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy

... as adjunctive therapy for patients with partial epilepsy with or without secondary generalization. ... were observed in either treatment group. About epilepsy epilepsy is defined by recurrent unprovoked seizures, or ...

New Research Shows: Neurofeedback is an 'Evidence-Based' Treatment for ADHD

... brain activity. This method was initially discovered for the treatment of epilepsy and from 1976 investigated further for the treatment of ADHD. This ... for each disorder. For example, a meta-analysis of EEG biofeedback in epilepsy is published in the same issue of EEG and Clinical Neuroscience ...

Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40%

... as early as week two of the study. LGS is a severe form of generalized epilepsy that develops in early childhood and is characterized by multiple types of ... said the study's lead author Tracy Glauser, MD, Director, Comprehensive epilepsy Program, Cincinnati Children's Hospital Medical Center, Ohio. ...

Cyberonics Provides Update on Depression Post-Approval Study

... The company developed and markets the Vagus Nerve Stimulation (VNS) Therapy(TM) System, which is FDA-approved for the treatments of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers pulsed electrical signals to the ...

Astrocytes Help Separate Man From Mouse

... makes the brain so interesting." To do the study, the team studied human brain tissue taken from 30 people who had had surgery, mostly to treat epilepsy or brain tumors. They compared the astrocytes in human brains to those in mice and rats. In addition to the findings above, the team noted additional ...

Archimedes Pharma Announces Successful Proof-of-Concept Results on Two Intranasal Development Projects

... being developed for the treatment of motor fluctuations or "off episodes" in Parkinson's disease and Acute Repetitive Seizures ("ARS") in refractory epilepsy patients respectively. Richard de Souza, CEO of Archimedes, said: "Both these trials have generated exciting results, highlighting the quality ...

Brain Waves Show Sound Processing Abnormalities in Autistic Children

... brain waves change with every sensation, thought and activity. It's like watching a movie of the brain in real time." Typically used for epilepsy evaluation, MEG can also be used to identify timing abnormalities in the brains of patients with autism. "We found that signatures of autism ...

Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health

... separate twins conjoined at the head without neurological damage. The hospital also provides treatment programs including dedicated pediatric epilepsy and sleep disorders centers, one of the nation's leading adolescent AIDS programs, treatment for chronic conditions such as asthma and diabetes, as ...

Anavex presents neuroprotective effects of Anavex 1-41 at the International Conference on Alzheimer's Disease 2008

... company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases such as Alzheimer's, epilepsy and depression. The company's proprietary SIGMACEPTOR(TM) Discovery Platform involves the rational design of drug compounds that fulfill specific ...

FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months

... Inc., focuses exclusively on providing solutions that improve neurological health. The company currently markets products for Alzheimer's disease, epilepsy and acute and preventive migraine treatment. In conjunction with internal and external research partners, Ortho-McNeil Neurologics continues to ...

Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia

... acids in cardiovascular disease. Amarin's CNS development pipeline includes programs in myasthenia gravis, Huntington's disease, Parkinson's disease, epilepsy and memory. Amarin is listed in the U.S. on the NASDAQ Capital Market ("AMRN"). Disclosure Notice The information contained in this document is ...

TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate

... development and management of clinical care and medical education policy for 29 affiliated hospitals. In addition, he was President of the epilepsy Society of Southern New York. Dr. Tuchman is a frequent speaker about neuroscience topics at academic meetings. "There's a growing body ...

Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate

... within a 24-hour period in adults and a 12-hour period in children. ARS, also called seizure clusters, occurs in a small subset of patients with epilepsy who regularly experience breakthrough seizures in flurries or clusters despite treatment with a regimen of anti-epileptic drugs. ARS is a rare ...

Tezampanel, TorreyPines Therapeutics' Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego

... of acute migraine, our preclinical and clinical data demonstrate potential utility across a range of pain conditions, as well as diseases such as epilepsy and anxiety. These exciting results from the UCSD researchers further reinforce our belief in the versatility of this first-in-class compound." ...

Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline

... imidafenacin, developed by Kyorin Pharmaceutical, Ono Pharmaceutical and LG Life Sciences. Fourth is a drug for one of the most severe forms of epilepsy (Lennox- Gastaut Syndrome or LGS), affecting approximately 5% of the children who have the disease. Eisai's rufinamide, licensed from Novartis, is ...

Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2 Study Data in Neurology

... to improve the management of patients whose epilepsy is not controlled by current medications," said ... and Safety Trials for Partial Onset epilepsy (RESTORE), two large, pivotal Phase 3 trials that ... safety and efficacy of retigabine in refractory epilepsy patients who are receiving one, two or three ...

UCB Announces Positive Top-Line Phase III Results for Keppra as Adjunctive Therapy for Partial Onset Seizures in Paediatric Patients from One Month to Less than Four Years of Age

... prevalent neurological conditions. The effects of epilepsy on a child's psychological and social development ... of age and older with idiopathic generalized epilepsy (IGE). Keppra® tablets and oral solution are ... of age and older with idiopathic generalized epilepsy experiencing primary generalized tonic-clonic ...

New Data Shows Once a Day Lamictal XR is Effective in Treating Patients with Partial Seizures

... as add-on treatment in patients with partial epilepsy with and without secondary generalization. ... seizure frequency among the groups. ABOUT epilepsy Epilepsy, defined by recurrent unprovoked ... cause of epilepsy is unknown. According to the epilepsy Foundation, more than three million Americans of ...

Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference

... efforts are focused on gene therapy for treating Parkinson's disease, epilepsy and other neurodegenerative and metabolic disorders. Neurologix's ... disease and with additional trials in that indication and in epilepsy planned. Contact Neurologix, Inc. Marc Panoff, 201-592-6451 Chief ...

Icagen Terminates Phase III ASSERT Study

... an agreement with the McNeil Pediatrics Division of McNeil-PPC, Inc., a subsidiary of Johnson & Johnson. -0- - lead compounds for epilepsy and neuropathic pain, for which the Company is conducting preclinical studies; -0- - a lead compound for atrial fibrillation, for which the ...

Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Company's Investigational Drug to Treat Cocaine and Methamphetamine Addiction

... Vigabatrin has been marketed over the past decade in more than 30 countries under the brand name Sabril(R) as a secondary treatment for adult epilepsy and as a primary treatment for the management of infantile spasms, known as West Syndrome. Commenting on today's news and the Company's product ...

Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinson's Disease

... nervous system utilizing gene therapies. The Company's initial development efforts are focused on gene therapy for treating Parkinson's disease, epilepsy and other neurodegenerative and metabolic disorders. Neurologix's core technology, "NLX," is currently in the clinical development stages, having ...